- The European Commission approves Actavis (ACT +1.1%) subsidiary Durata Therapeutics International's Xydalba (dalbavancin) for the treatment of adult patients acute bacterial skin and skin structure infections (ABSSSI), the first once-weekly intravenous (IV) antibiotic approved for this indication.
- Xydalba will be commercialized by Rome, Italy-based Angelini.
- The product is marketed in the U.S. under the brand name Dalvance.
- Actavis acquired Durata in October.
- Previously: Actavis to buy Durata (Oct. 6, 2014)